Cargando…

The survival benefit and safety of No. 12a lymphadenectomy for gastric cancer patients with distal or total gastrectomy

There has still not been a consensus in aspects of survival benefit and safety on No.12a lymph nodes (LNs) dissection for gastric cancer patients. This study was aimed to evaluate this issue for patients with distal or total gastrectomy. Patients were retrospectively divided into 12aD+ group (with N...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Kun, Chen, Hai-Ning, Liu, Kai, Zhang, Wei-Han, Chen, Xin-Zu, Chen, Xiao-Long, Zhou, Zong-Guang, Hu, Jian-Kun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4951326/
https://www.ncbi.nlm.nih.gov/pubmed/26959745
http://dx.doi.org/10.18632/oncotarget.7930
_version_ 1782443685440389120
author Yang, Kun
Chen, Hai-Ning
Liu, Kai
Zhang, Wei-Han
Chen, Xin-Zu
Chen, Xiao-Long
Zhou, Zong-Guang
Hu, Jian-Kun
author_facet Yang, Kun
Chen, Hai-Ning
Liu, Kai
Zhang, Wei-Han
Chen, Xin-Zu
Chen, Xiao-Long
Zhou, Zong-Guang
Hu, Jian-Kun
author_sort Yang, Kun
collection PubMed
description There has still not been a consensus in aspects of survival benefit and safety on No.12a lymph nodes (LNs) dissection for gastric cancer patients. This study was aimed to evaluate this issue for patients with distal or total gastrectomy. Patients were retrospectively divided into 12aD+ group (with No.12a dissection) and 12aD–group (without No.12a dissection). Clinicopathologic characteristics, survival rate, morbidity and mortality were compared. There were 670 patients in 12aD+ group, while 567 in 12aD–group. The baselines between the two groups were comparable. The No.12a LNs metastasis ratio was 11.6% and higher in lower third tumor. The metastasis of No.5 LNs, N stage and M stage were correlated to metastasis of No.12a LNs. There was no difference in morbidity nor mortality between the two groups. The 5-year overall survival rates (5-y OS) were 59.6% and 55.1% in 12aD+ group and 12aD–group respectively (P = 0.075). The 5-y OS of patients with negative and positive No.12a LNs were 62.3% and 24.1%. The survival of stage III patients with No.12a positive was better than that of stage IV patients. The 5-y OS were better in 12aD+ group for patients with ages more than 60, lower third tumor, distal gastrectomy, N3 status, or III stages compared with 12aD–group. No.12a lymphadenectomy was independently better prognostic factors for stage III patients. No.12a LNs metastasis should not be considered as distant metastasis. No.12a lymphadenectomy can be performed safely and should be indicated for potentially curable progressive stage tumors requiring distal gastrectomy and might be reserved in patients with stage I or II, or upper third tumor.
format Online
Article
Text
id pubmed-4951326
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-49513262016-07-21 The survival benefit and safety of No. 12a lymphadenectomy for gastric cancer patients with distal or total gastrectomy Yang, Kun Chen, Hai-Ning Liu, Kai Zhang, Wei-Han Chen, Xin-Zu Chen, Xiao-Long Zhou, Zong-Guang Hu, Jian-Kun Oncotarget Research Paper There has still not been a consensus in aspects of survival benefit and safety on No.12a lymph nodes (LNs) dissection for gastric cancer patients. This study was aimed to evaluate this issue for patients with distal or total gastrectomy. Patients were retrospectively divided into 12aD+ group (with No.12a dissection) and 12aD–group (without No.12a dissection). Clinicopathologic characteristics, survival rate, morbidity and mortality were compared. There were 670 patients in 12aD+ group, while 567 in 12aD–group. The baselines between the two groups were comparable. The No.12a LNs metastasis ratio was 11.6% and higher in lower third tumor. The metastasis of No.5 LNs, N stage and M stage were correlated to metastasis of No.12a LNs. There was no difference in morbidity nor mortality between the two groups. The 5-year overall survival rates (5-y OS) were 59.6% and 55.1% in 12aD+ group and 12aD–group respectively (P = 0.075). The 5-y OS of patients with negative and positive No.12a LNs were 62.3% and 24.1%. The survival of stage III patients with No.12a positive was better than that of stage IV patients. The 5-y OS were better in 12aD+ group for patients with ages more than 60, lower third tumor, distal gastrectomy, N3 status, or III stages compared with 12aD–group. No.12a lymphadenectomy was independently better prognostic factors for stage III patients. No.12a LNs metastasis should not be considered as distant metastasis. No.12a lymphadenectomy can be performed safely and should be indicated for potentially curable progressive stage tumors requiring distal gastrectomy and might be reserved in patients with stage I or II, or upper third tumor. Impact Journals LLC 2016-03-05 /pmc/articles/PMC4951326/ /pubmed/26959745 http://dx.doi.org/10.18632/oncotarget.7930 Text en Copyright: © 2016 Yang et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Yang, Kun
Chen, Hai-Ning
Liu, Kai
Zhang, Wei-Han
Chen, Xin-Zu
Chen, Xiao-Long
Zhou, Zong-Guang
Hu, Jian-Kun
The survival benefit and safety of No. 12a lymphadenectomy for gastric cancer patients with distal or total gastrectomy
title The survival benefit and safety of No. 12a lymphadenectomy for gastric cancer patients with distal or total gastrectomy
title_full The survival benefit and safety of No. 12a lymphadenectomy for gastric cancer patients with distal or total gastrectomy
title_fullStr The survival benefit and safety of No. 12a lymphadenectomy for gastric cancer patients with distal or total gastrectomy
title_full_unstemmed The survival benefit and safety of No. 12a lymphadenectomy for gastric cancer patients with distal or total gastrectomy
title_short The survival benefit and safety of No. 12a lymphadenectomy for gastric cancer patients with distal or total gastrectomy
title_sort survival benefit and safety of no. 12a lymphadenectomy for gastric cancer patients with distal or total gastrectomy
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4951326/
https://www.ncbi.nlm.nih.gov/pubmed/26959745
http://dx.doi.org/10.18632/oncotarget.7930
work_keys_str_mv AT yangkun thesurvivalbenefitandsafetyofno12alymphadenectomyforgastriccancerpatientswithdistalortotalgastrectomy
AT chenhaining thesurvivalbenefitandsafetyofno12alymphadenectomyforgastriccancerpatientswithdistalortotalgastrectomy
AT liukai thesurvivalbenefitandsafetyofno12alymphadenectomyforgastriccancerpatientswithdistalortotalgastrectomy
AT zhangweihan thesurvivalbenefitandsafetyofno12alymphadenectomyforgastriccancerpatientswithdistalortotalgastrectomy
AT chenxinzu thesurvivalbenefitandsafetyofno12alymphadenectomyforgastriccancerpatientswithdistalortotalgastrectomy
AT chenxiaolong thesurvivalbenefitandsafetyofno12alymphadenectomyforgastriccancerpatientswithdistalortotalgastrectomy
AT zhouzongguang thesurvivalbenefitandsafetyofno12alymphadenectomyforgastriccancerpatientswithdistalortotalgastrectomy
AT hujiankun thesurvivalbenefitandsafetyofno12alymphadenectomyforgastriccancerpatientswithdistalortotalgastrectomy
AT yangkun survivalbenefitandsafetyofno12alymphadenectomyforgastriccancerpatientswithdistalortotalgastrectomy
AT chenhaining survivalbenefitandsafetyofno12alymphadenectomyforgastriccancerpatientswithdistalortotalgastrectomy
AT liukai survivalbenefitandsafetyofno12alymphadenectomyforgastriccancerpatientswithdistalortotalgastrectomy
AT zhangweihan survivalbenefitandsafetyofno12alymphadenectomyforgastriccancerpatientswithdistalortotalgastrectomy
AT chenxinzu survivalbenefitandsafetyofno12alymphadenectomyforgastriccancerpatientswithdistalortotalgastrectomy
AT chenxiaolong survivalbenefitandsafetyofno12alymphadenectomyforgastriccancerpatientswithdistalortotalgastrectomy
AT zhouzongguang survivalbenefitandsafetyofno12alymphadenectomyforgastriccancerpatientswithdistalortotalgastrectomy
AT hujiankun survivalbenefitandsafetyofno12alymphadenectomyforgastriccancerpatientswithdistalortotalgastrectomy